EU Accelerated Assessment Tracker
Sanofi appears to have failed to convince the European Medicines Agency that its just-filed marketing authorization application for isatuximab should be granted accelerated assessment. AB Science's request regarding its planned MAA for masitinib has been rejected and Alnylam is declining to disclose the fate of its request relating to givosiran. See our latest updates in the tracker below.
You may also be interested in...
The UK scheme allows patients with early access to promising new unlicensed medicines when there is a clear unmet medical need.
Mitsubishi and Emmaus Life Sciences are among the companies that will find out this week whether the European Medicines Agency's drug evaluation committee, the CHMP, will recommend their new products for EU approval.
Sponsors of a raft of new products will find out this week if the European Medicines Agency’s medicines evaluation committee, the CHMP, is convinced the therapies are ready for marketing.